Insider · CIK 0001180432

MARAGANORE JOHN

Reports to the SEC for 12 companies · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001180432

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-22	RAPPRapport Therapeutics, Inc.P Purchase	Director	PPurchase	+1,172 sh	$26.92	+$31.5K	9,411
2026-10-22	RAPPRapport Therapeutics, Inc.P Purchase	Director	PPurchase	+8,239 sh	$26.38	+$217K	8,239
2026-10-19	CTYCITY THERAPEUTICS, INC.C Conversion	Director	CConversion	+611K sh	—	—	1,470,692
2026-10-19	CTYCITY THERAPEUTICS, INC. · Series Seed convertible preferred stockC Conversion	Director	CConversion	−500K sh	—	—	0
2026-10-19	CTYCITY THERAPEUTICS, INC. · Series A convertible preferred stockC Conversion	Director	CConversion	−56.1K sh	—	—	0
2026-10-15	CTYCITY THERAPEUTICS, INC. · Stock Option (Right to Buy)A Award	Director	AAward	+22.6K sh	—	—	22,649
2026-07-10	TAKTAKEDA PHARMACEUTICAL CO LTD · Tax Obligation AwardD Disposition to Issuer	Director	DDisposition to Issuer	−1,152 sh	$4931.20	−$5.68M	0
2026-07-01	TAKTAKEDA PHARMACEUTICAL CO LTDA Award	Director	AAward	+3,800 sh	—	—	10,400
2026-07-01	TAKTAKEDA PHARMACEUTICAL CO LTD · Tax Obligation AwardA Award	Director	AAward	+1,319 sh	—	—	1,319
2026-06-24	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,068 sh	—	—	6,068
2026-06-10	RAPPRapport Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15.2K sh	—	—	15,200
2026-06-03	BEAMBeam Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19.7K sh	—	—	19,676
2026-05-04	COAGHemab Therapeutics Holdings, Inc.C Conversion	Director	CConversion	+18K sh	—	—	17,974
2026-05-04	COAGHemab Therapeutics Holdings, Inc.C Conversion	Director	CConversion	+18K sh	—	—	35,948
2026-05-04	COAGHemab Therapeutics Holdings, Inc. · Series B Preferred StockC Conversion	Director	CConversion	−817 sh	—	—	0
2026-05-04	COAGHemab Therapeutics Holdings, Inc. · Series C Preferred StockC Conversion	Director	CConversion	−817 sh	—	—	0
2026-01-29	COAGHemab Therapeutics Holdings, Inc. · Warrants (Right to Buy)A Award	Director	AAward	+107K sh	—	—	107,338
2025-06-25	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2025-06-17	RAPPRapport Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+21.9K sh	—	—	21,850
2025-06-04	BEAMBeam Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+33.7K sh	—	—	33,662
2024-06-18	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16K sh	—	—	16,000
2024-06-05	BEAMBeam Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+23.1K sh	—	—	23,114
2023-06-29	PROKPROKIDNEY CORP. · Director stock option (right to buy)A Award	Director	AAward	+48.1K sh	—	—	48,128
2023-06-15	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12K sh	—	—	12,000
2023-06-06	BEAMBeam Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16.5K sh	—	—	16,532
2022-09-20	AGIOAGIOS PHARMACEUTICALS, INC.G Gift	Director	GGift	−1,500 sh	—	—	28,528
2022-09-01	BEAMBeam Therapeutics Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10.4K sh	—	—	10,391
2022-07-11	PROKPROKIDNEY CORP. · Class B Ordinary SharesA Award	Director	AAward	+614K sh	—	—	614,013
2022-07-11	PROKPROKIDNEY CORP. · Common Units in ProKidney LPA Award	Director	AAward	+614K sh	—	—	614,013
2022-06-21	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitA Award	Director	AAward	+4,975 sh	—	—	4,975
2022-06-21	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director	AAward	+29.3K sh	—	—	29,307
2022-05-20	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+1,585 sh	—	—	30,028
2022-05-20	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitM Exercise/Conversion	Director	MExercise/Conversion	−1,585 sh	—	—	0
2022-01-18	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+24K sh	—	—	24,000
2021-12-22	ALNYALNYLAM PHARMACEUTICALS, INC.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−6,315 sh	$189.13	−$1.19M	227,984
2021-12-22	ALNYALNYLAM PHARMACEUTICALS, INC.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−2 sh	$190.50	−$381	227,982
2021-12-22	ALNYALNYLAM PHARMACEUTICALS, INC.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−319 sh	$186.02	−$59.3K	227,663
2021-12-21	ALNYALNYLAM PHARMACEUTICALS, INC.A Award	Director, Chief Executive Officer	AAward	+14.2K sh	—	—	234,299
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+1,036 sh	$96.45	+$99.9K	215,801
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+1,124 sh	$88.95	+$100K	216,925
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+839 sh	$119.13	+$100K	217,764
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+2,368 sh	$42.22	+$100K	220,132
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−2,368 sh	—	—	22,632
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−1,124 sh	—	—	63,876
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−1,036 sh	—	—	73,964
2021-12-10	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−839 sh	—	—	51,661
2021-11-12	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+34K sh	$7.10	+$241K	248,743
2021-11-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−10.4K sh	$170.36	−$1.77M	238,378
2021-11-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−7,742 sh	$171.35	−$1.33M	230,636
2021-11-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−14.5K sh	$172.22	−$2.5M	216,118

Recent filings

Accepted (ET)
Oct 224
MARAGANORE JOHN0001193125-26-429071
SEC(opens sec.gov)
Oct 194
MARAGANORE JOHN0001104659-26-116963
SEC(opens sec.gov)
Jul 64
MARAGANORE JOHN0001395064-26-000275
SEC(opens sec.gov)
Jun 254
MARAGANORE JOHN0001193125-26-283137
SEC(opens sec.gov)
Jun 104
MARAGANORE JOHN0001193125-26-266155
SEC(opens sec.gov)
Jun 54
MARAGANORE JOHN0001193125-26-259524
SEC(opens sec.gov)
May 44
MARAGANORE JOHN0001193125-26-204048
SEC(opens sec.gov)
Jun 264
MARAGANORE JOHN0000950170-25-090582
SEC(opens sec.gov)
Jun 184
MARAGANORE JOHN0000950170-25-087902
SEC(opens sec.gov)
Jun 64
MARAGANORE JOHN0000950170-25-083053
SEC(opens sec.gov)

Companies

Address

RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100

BOSTON, MA, 02110